Thirty-day mortality and long-term survival following surgery for prosthetic endocarditis: a study from the UK heart valve registry

被引:60
作者
Edwards, MB [1 ]
Ratnatunga, CP [1 ]
Dore, CJ [1 ]
Taylor, KM [1 ]
机构
[1] Hammersmith Hosp, Dept Cardiothorac Surg, United Kingdom Heart Valve Registry, London W12 0HS, England
关键词
prosthetic valve endocarditis; operative mortality; long-term survival;
D O I
10.1016/S1010-7940(98)00148-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the 30-day mortality, long-term survival and freedom from reoperation following surgery for prosthetic endocarditis (PVE). Method: A retrospective analysis of data from the UK Heart Valve Registry of 322 patients who had undergone single mechanical/bioprosthetic valve replacement for PVE between 1 January 1986 and 31 December 1996, The mean age was 54.9 +/- 12.8 years and 213 (66.1%) were males. There were 170 aortic and 152 mitral valve implantations. Eighty-five (26%) of the infected valves were bioprosthetic and 237 (74%) were mechanical. Of the new prostheses implanted 53 (17%) were bioprosthetic and 269 (83%) were mechanical. Of those with infected bioprostheses, 50 (15.2%) had mechanical valves at redo surgery, whilst 219 (68.3%) of infected mechanical prostheses were re-replaced by mechanical prostheses. The follow-up was 98% complete with a total of 1084.9 patient years. Results: The 30-day mortality was 63 (19.9%; 95%CI 15.9-24.7%). There were 85 late deaths. One, 5 and 10 year survival rates were 67.1% (61.6-72.0%), 55.0% (49.0-60.7%) and 37.6% (27.9-47.2%), respectively. Age was the only significant determinant of 30-day mortality (P = 0.04). Age (P = 0.001) and explanting of infected bioprosthesis and replacement by mechanical valve (P = 0.04) determined long-term survival (P = 0.001). The incidence of re-reoperation was 9.9%. Freedom from reoperation for PVE was 88.4, 87.3 and 87.3% at 1, 5 and 10 years, respectively. Explanting of bioprosthesis and replacement by mechanical valve (P < 0.001) and reoperation within 60 days of native valve replacement (P = 0.02) were determinants of reoperation for PVE. Freedom from death or reoperation was 61.1, 50.6 and 34.2% at 1, 5 and 10 years, respectively. Age (P = 0.003), explanting of bioprosthesis and replacement by mechanical valve (P = 0.002) and the period between prosthetic re-replacement (P = 0.04) determined freedom from death or reoperation. Conclusion: Operation for PVE carries a high 30-day mortality and reduced long-term survival. There is no evidence that type of prosthesis used for re-reoperation determines survival or freedom from re-reoperation. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:156 / 164
页数:9
相关论文
共 27 条
  • [1] Antunes M J, 1992, J Heart Valve Dis, V1, P15
  • [2] Bortolotti U, 1994, J Heart Valve Dis, V3, P81
  • [3] BOSCH X, 1984, J THORAC CARDIOV SUR, V88, P567
  • [4] CALDERWOOD SB, 1986, J THORAC CARDIOV SUR, V92, P776
  • [5] Camacho M T, 1995, Semin Thorac Cardiovasc Surg, V7, P32
  • [6] David T E, 1995, Semin Thorac Cardiovasc Surg, V7, P47
  • [7] THE RISK OF INFECTIVE ENDOCARDITIS AFTER CARDIAC SURGICAL AND INTERVENTIONAL PROCEDURES
    DEGEVIGNEY, G
    POP, C
    DELAHAYE, JP
    [J]. EUROPEAN HEART JOURNAL, 1995, 16 : 7 - 14
  • [8] Farina G, 1994, J Heart Valve Dis, V3, P165
  • [9] GROVER FL, 1994, J THORAC CARDIOV SUR, V108, P207
  • [10] HUSEBYE DG, 1983, J THORAC CARDIOV SUR, V86, P543